ADARx Pharmaceuticals, Inc. (ADRX) - What Are Analysts Thinking About This Stock?

Key Points

• Analysts are broadly positive: ADARx Pharmaceuticals has a “Moderate Buy” consensus from five analysts, including four buy ratings and one hold. The average 12-month price target is $35, versus a recent share price of $17.68.
• Recent coverage has been favorable: UBS and TD Cowen initiated coverage with buy ratings, while Morgan Stanley assigned an overweight rating and a $32 target. Zacks Research and Wall Street Zen upgraded the stock to hold.
• Insiders have been buying: Insiders purchased 3.26 million shares worth approximately $55.4 million over the past quarter, including a major shareholder’s $27.2 million purchase at $17 per share.

Shares of ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $35.00.

ADRX has been the subject of a number of recent analyst reports. Zacks Research raised ADARx Pharmaceuticals to a "hold" rating in a research report on Wednesday. UBS Group started coverage on ADARx Pharmaceuticals in a research report on Tuesday. They issued a "buy" rating and a $35.00 price objective on the stock. TD Cowen initiated coverage on ADARx Pharmaceuticals in a research note on Tuesday. They set a "buy" rating on the stock. Wall Street Zen raised ADARx Pharmaceuticals to a "hold" rating in a research note on Saturday, October 3rd. Finally, Morgan Stanley assumed coverage on ADARx Pharmaceuticals in a report on Tuesday. They set an "overweight" rating and a $32.00 target price for the company.

Insider Activity at ADARx Pharmaceuticals

In related news, major shareholder Sr One Capital Management, Llc purchased 1,600,000 shares of the business's stock in a transaction that occurred on Monday, September 28th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the acquisition, the insider directly owned 5,554,094 shares in the company, valued at approximately $94,419,598. The trade was a 40.46% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Erez Chimovits acquired 61,516 shares of ADARx Pharmaceuticals stock in a transaction on Monday, September 28th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $1,045,772.00. Following the completion of the transaction, the director owned 9,292,025 shares in the company, valued at approximately $157,964,425. This trade represents a 0.67% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 3,261,516 shares of company stock worth $55,445,772 over the last quarter.

ADARx Pharmaceuticals Trading Up 3.2%

NASDAQ ADRX opened at $17.68 on Friday. ADARx Pharmaceuticals has a 1 year low of $16.61 and a 1 year high of $23.21.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company's platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.

ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.